Physician profile
Beth T Sachrison
NPI 1548256290
$2,967.45
in general payments reported to CMS, 2019-2025
22 companies · $512 in 2025
The $512 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $440 · 2021: $450 · 2022: $345 · 2023: $604 · 2024: $260 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $603.29 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $459.90 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $442.91 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $270.54 | 2019-2021 | |
| Sanofi Pasteur INC. | $244.88 | 2019-2025 | |
| Kaleo, INC. | $203.98 | 2019-2022 | |
| Tris Pharma INC | $128.19 | 2020-2022 | |
| Corium, LLC | $95.65 | 2023 | Azstarys, Azstarys |
| Glaxosmithkline, LLC. | $69.78 | 2019-2025 | Bexsero |
| Sobi, INC | $67.58 | 2019-2023 | |
| Seqirus USA INC | $60.26 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Avion Pharmaceuticals | $46.06 | 2023 | Methylphenidate Hydrochloride |
| Xeris Pharmaceuticals, INC. | $45.86 | 2023-2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $41.92 | 2023-2024 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $39.63 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $36.04 | 2025 | Neffy |
| Genentech USA, INC. | $24.10 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $19.35 | 2019 | |
| Alk-Abello, INC | $18.75 | 2025 | Neffy |
| Lnhc, INC | $18.73 | 2025 | Zelsuvmi |
| Shire North American Group INC | $15.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.48 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Sachrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.